THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY

被引：0
|
作者：
Erhardt, W. [1 ]
Bergenheim, K.
Townsend, R. [2 ]
Puelles, Fernandez de Troconiz J. [3 ]
McEwan, P. [2 ]
机构：
[1] Bristol Myers Squibb GmbH & Co KGaA, Munich, Germany
[2] CRC, Cardiff, S Glam, Wales
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72102-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A291 / A292
页数：2
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [2] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [3] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [4] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [5] Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany A Cardiff Diabetes Model Analysis
    Erhardt, Wilma
    Bergenheim, Klas
    Duprat-Lomon, Isabelle
    McEwan, Phil
    CLINICAL DRUG INVESTIGATION, 2012, 32 (03) : 189 - 202
  • [6] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [7] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [8] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [9] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
    Ramirez de Arellano, A.
    Brosa, M.
    Franch, J.
    Mauricio, D.
    Alvarez, C.
    Sanchez-Zamorano, M.
    De Rivas, B.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [10] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
12345